Niowave Expands 10-Year Actinium-225 Supply Agreement with AstraZeneca for Advanced Cancer Therapies
核心洞察
Niowave (搜索) has expanded its existing supply agreement with AstraZeneca to a 10-year commitment for delivering Actinium-225 (搜索), a critical radioisotope for next-generation cancer treatments.
The agreement addresses the limited global supply of Ac-225, which emits highly potent alpha particles that precisely destroy tumor cells while minimizing damage to healthy tissue.
AstraZeneca will use the isotope supply to advance its growing portfolio of radioconjugates targeting prostate and other difficult-to-treat cancers.
Niowave (搜索) Inc., a U.S.-based global leader in medical radioisotope production, has expanded its existing supply agreement with AstraZeneca to a 10-year commitment for delivering Actinium-225 (搜索) (Ac-225), following AstraZeneca's decision to exercise its option to increase capacity. The agreement secures a reliable and scalable supply of this critical isotope to advance AstraZeneca's growing portfolio of radioconjugates for cancer treatment.
Strategic Partnership Addresses Critical Supply Gap
The expanded partnership underscores the critical importance of securing dependable isotope supply as AstraZeneca advances radioconjugates for prostate and other difficult-to-treat cancers. Radioconjugates are a type of cancer treatment that use radioactive particles to target and destroy cancer cells with precision.
"Our expanded agreement with AstraZeneca underscores Niowave (搜索)'s central role in scaling high-quality production of medical radioisotopes for the development of targeted cancer treatments," said Mike Zamiara, CEO of Niowave. "We are pleased to play a role in ensuring that AstraZeneca's promising pipeline of radioconjugates have the isotope supply they need."
Actinium-225's Therapeutic Potential
Ac-225 is one of the most promising radioisotopes in oncology as its emitted alpha particles deliver highly potent, DNA-damaging energy, enabling precise destruction of tumor cells while limiting harm to surrounding healthy tissue with targeted modalities like radioconjugates. Despite its potential, global supply of Ac-225 remains limited, creating a significant bottleneck for the development of these advanced cancer therapies.
Advanced Production Technology
Niowave (搜索)'s proprietary superconducting linear accelerator technology and radiochemistry provide sustainable, U.S.-based production to address the supply shortage. The company, founded in 2005 and headquartered in Lansing, Michigan, specializes in developing and operating superconducting electron linear accelerators and advancing radiochemistry procedures for medical isotope production.
The 10-year supply agreement represents a significant commitment to ensuring the availability of Ac-225 for AstraZeneca's expanding radioconjugate pipeline, which targets some of the most challenging cancers to treat. This partnership highlights the growing importance of reliable isotope supply chains in advancing next-generation cancer treatments that offer improved precision and reduced side effects compared to traditional therapies.